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C,':'~ Abstract 
Dilantin, diphenylhydantoin (DPH), is an anticonvulsant 
drug used to control the disorder known as epilepsy. 
Dilantin, however, is a known human teratogen and pregnant 
females taking this drug have an increased risk of 
spontaneous miscarriages and of giving birth to babies with 
fetal hydantoin syndrome. To study the effects of Dilantin 
at preimplantation stages, varying concentrations of the 
drug were added directly to cuI 
tures of 2-cell mouse embryos. After two days of culture, 
the embryos were analyzed for percent development beyond the 
two cell stage. Although effects of Dilantin were observed, 
no true dosage response curve was found in the therapeutic 
range in the cultures where Dilantin was added directly. 
cultures containing 5 ~g/ml DPH promoted normal development 
to morula and blastocyst stages (46%). DPH at 10 and 20 
~g/ml concentrations promoted development to the 4-8 cell 
stage but morula and blastocyst stages were reduced (40.5% 
and 53%). This effect became more severe at 50 and 100 
~g/ml levels. Further studies that investigate whether the 
teratogenic agent is the parent drug or actually a metabolic 
intermediate of DPH were performed by addition of a 
microsomal S9 fraction to cultures of two cell mouse 
embryos. The S9 fraction alone was found to not be 
teratogenic to the embryos itself, however, the addition of 
DPH and S9 fraction increased the toxic effect of the drug. 
Introduction 
Epilepsy is a disorder which can be controlled through 
the use of anticonvulsant drugs. However, up to 30% of 
epileptic mothers on anticonvulsant medication give birth to 
babies with fetal hydantoin syndrome (Hanson, 1986). This 
syndrome is characterized by various morphological 
deformities (Hanson, 1986, Hill, 1974). Considering that 
0.3-0.5% of the population are female epileptics, the 
teratogenesis of anticonvulsants is an extremely important 
problem (Finnell, 1981). Many studies at postimplantation 
stages have yielded conflicting results. Pregnant 
epileptics also have an increased risk of early spontaneous 
miscarriages which may suggest an effect before implantation 
into the uterus (Annegers, et al., 1974, Biale, et al.1975, 
and Hill, et al., 1974). To study the preimplantation 
effects of an anticonvulsant drug, Dilantin (DPH), in vitro, 
different concentrations of the drug were added directly to 
cultures of two cell mouse embryos. After two days of 
culture, the embryos were analyzed for the percent 
development to each of the preimplantation stages. The 
results of this study will hopefully lead to a better 
understanding of how anticonvulsants cause birth defects and 
miscarriages. In order to fully comprehend this problem 
background information on epilepsy and anticonvulsants, the 
metabolism of Dilantin, mouse embryonic development, and 
embryo culture are required. 
Epilepsy and Anticonvulsants: 
Dilantin, diphenylhydantoin (DPH) , is an anticonvulsant 
drug used to control epilepsy (Hanson, 1986). Dilantin, 
however, is a known human teratogen and pregnant females 
taking this drug have an increased risk of giving birth to 
children with fetal hydantoin syndrome (Annegers et al., 
1974, Biale et al., 1975, Chatot et al., 1984). Fetal 
hydantoin syndrome is characterized by cleft lip and/or 
palate, craniofacial malformations, hypoplasia of the 
digits, mental retardation, urogenital defects, ventricular 
septal defects and other morphological defects (Hanson, 
1986, Hill et al., 1974). Attempts to identify causes of 
this teratogenicity in humans have resulted in conflicting 
reports. Shapiro et ale (1976) reported that the epileptic 
disorder itself was the main cause of malformations. In 
1981, Richard Finnell developed a mouse model to study the 
effects of anticonvulsant drugs. Finnell developed a test 
animal that closely approximated the human epileptic 
disorder which had spontaneous seizures that could be 
controlled or eliminated with the oral administration of 
anticonvulsants. The plasma drug concentrations of these 
mice fell within the human therapeutic level, and the 
offspring of these mice exhibited defects similar to human 
fetal hydantoin syndrome (1981). The experimental data 
showed that the incidence of animals born with malformations 
increased with an increased level of the drug (Finnell, 
1981). Finnell's model demonstrated that the anticonvulsant 
drug was the cause of the increased risk of birth defects, 
not the epilepsy (1981). Karolyi found a difference in the 
susceptibility of different strains of mice to 
anticonvulsant drug teratogenicity for example C57BL/6J 
strain is more susceptible, wheras A/J is less susceptible. 
Chatot et ale (1984) found that when anticonvulsants were 
added directly to rat embryo cultures, there was no direct 
effect of the drug on the embryos, suggesting that the 
active teratogen could be a metabolite and not the parent 
drug. 
There are many other antiepileptic drugs used to 
control seizures, not just Dilantin. It is possible that 
phenobarbital and carbamezepine (other frequently used 
anticonvulsant drugs) work in the same way as DPH. All of 
these compounds contain an aromatic ring and use aromatic 
hydroxylation as a major metabolic pathway (Spielberg et 
al., 1981). These reactions may have active arene oxides as 
intermediates which can be toxic (Jerina and Daly, 1974). 
Spielberg et ale (1981) found that four anticonvulsants were 
toxic only with the addition of a microsomal system 
(phenobarbital and DPH were included in that study). 
Dilantin is often used in combinations with 
phenobarbital and/or carbamezepine, although monotherapy is 
the hoped for method of seizure control. These epileptic 
patients must continue taking the medication even during 
pregnancy. The damage to the fetus from anoxia if a seizure 
were to occur could be greater than the defects that can 
result from anticonvulsant drugs. 
Metabolism of Dilantin: 
Metabolism of drugs and other foreign agents is a 
detoxification mechanism of biological systems. cytochrome 
P-450 and its subsequent isozymes are found in the liver 
(highest concentration), the intestine and the kidney of 
rats, mice, and humans and are used to metabolize drugs to a 
phenol for final excretion from the body (de Waziers et al., 
1986, Jerina and Daly, 1974). However, during the 
conversion of anticonvulsants to their phenolic metabolites, 
there are arene oxide intermediates which are formed (Jerina 
and Daly, 1974, Martz et al., 1977, Spielberg et al., 1981). 
Arene oxides are extremely reactive and can bind covalently 
to cellular macromolecules including DNA, RNA, and protein 
(Jerina and Daly, 1974, Martz et al., 1977, Oesch, 1976, 
Shanks et al., 1989, Spielberg et al., 1981). This binding 
can result in mutations of genetic material, cell death, and 
birth defects (Spielberg, 1982). 
The oxidative metabolites of anticonvulsant drugs 
created by cytochrome P450 are usually removed through the 
use of epoxide hydrolase (Buehler et al., 1990) (See Figure 
1). Microsomal epoxide hydrolase catalyzes the hydrolysis 
of arene oxides to diols. Epoxide hydrolase is found in the 
endoplasmic reticulum and the nuclear envelope of cells 
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Figure 1: Metabolism of DHantin in tissues (Mukhtar, 1979). 
where it is associated with the cytochrome P450 system. The 
cytochrome P450 enzymes react with the DPH to form the arene 
oxide, then the epoxide hydrolase enzyme catalyzes the 
reaction which converts the arene oxide to the final 
phenolic metabolite which can then be excreted from the body 
(Mukhtar et al., 1979). The cytochrome P450 enzymes can 
further metabolize that phenol to a highly electrophilic 
diol epoxide that is not a good substrate for epoxide 
hydrolase but can form covalent bonds with cell 
macromolecules (Jerina and Daly, 1974). These reactions 
occur on the membranes of cells and not only detoxify the 
drug but may also activate it to form one or more 
teratogenic intermediates in the reaction (de Montellano, 
1986, Mukhtar et al., 1979). In support of this suggestion 
Shanks et al. (1989) found that the addition of a cytochrome 
P450 microsomal system to preimplantation mouse embryo 
cultures increased the toxicity of Dilantin. 
Genetics of Metabolism: 
Although not much is known about the enzymes and 
genetics surrounding metabolism of anticonvulsant drugs in 
animals, there have been studies conducted concerning 
humans. Spielberg et al. (1981) investigated the 
metabolites of DPH through an in vitro assay using human 
lymphocytes. He used lymphocytes because they are easily 
obtained and they contain defenses against metabolites (i.e. 
epoxide hydrolase) (Spielberg et al., 1981). A microsomal 
system was prepared by injecting mice with phenobarbital in 
order to induce cytochrome P450 microsomes (Speilberg et 
al., 1981). This microsomal protein fraction was then 
incubated with DPH and the lymphocytes which were obtained 
from a human blood sample (Spielberg et al., 1981). 
Spielberg et al. (1981) also added TCPO, an inhibitor of 
epoxide hydrolase, to one culture. The dose-response curves 
for anticonvulsant toxicity with a microsomal system show 
that at high concentrations of DPH, there was a direct toxic 
effect of the drug on the cells, however, within actual 
therapeutic plasma levels, there was no or minimal toxicity 
(Spielberg et al., 1981). When the epoxide hydrolase 
activity was inhibited by the addition of the TCPO, the 
percentage of dead cells after sixteen hours of incubation 
increased from 10-20% (without TepO) to 40-50% within the 
therapeutic range (Spielberg et al., 1981). Spielberg's 
results suggest that an intermediate in the metabolism of 
Dilantin which is usually removed by a reaction catalyzed by 
epoxide hydrolase may be the actual teratogen (Spielberg et 
al., 1981). 
Buehler et al. in 1990 analyzed a random sample of 
pregnant women for their level of epoxide hydrolase 
activity. He then ran a chromatographic assay which 
revealed a "trimodal distribution" of the levels of 
activity, one high, an intermediate activity, and one low 
were observed (Buehler et al., 1990). This distribution is 
characteristic of an enzyme that is regulated by a single 
gene with two allelic forms (Buehler et al., 1990). The low 
microsomal epoxide hydrolase activity ranged from 0-50% of 
the standard with a mean of 31%. This low activity could be 
of the genotype "ee" or the homozygous recessive. The 
intermediate activity would then be the heterozygous 
condition, "Ee," and was represented by the range from 50-
75% of the standard with a mean of 59%. Finally the high 
enzyme activity which ranged from 75-100% of the standard 
with a mean of 94% represented the homozygous dominant, 
"EE" (Buehler et al., 1990) (see figure two). 
To determine patient risk for teratogenicity, the 
genotype of both the mother and the fetus must be 
considered; some metabolism can occur in maternal tissue, 
placenta and fetal tissues. Those patients that would be at 
of epoxide hydrolase (Bueh ler, 1990). 
risk for giving birth to babies with fetal hydantoin 
syndrome would be those with epoxide hydrolase activity at 
the low end of the activity range who were exposed to DPH 
during the pregnancy and also those fetuses that are the 
product of two heterozygotes (Buehler et al., 1990). These 
infants that would have the "at risk" genotype when exposed 
to the anticonvulsant in utero would not readily metabolize 
the intermediate arene oxide to the final phenolic 
metabolite. This would, in turn, make those fetuses more 
susceptible to the teratogenic effects of the anticonvulsant 
(Buehler et al., 1990). 
Buehler et ale (1990) then concluded that if the level 
of epoxide hydrolase activity was a major factor in the 
severity of the final malformations, it would be possible to 
use that level as a pre indication of whether a patient would 
give birth to a baby with fetal hydantoin syndrome. Buehler 
et ale (1990) tested his theory by investigating the 
pregnancies of 19 epileptic women who were treated only with 
DPH. Amniocentesis and examination of epoxide hydrolase 
activity in the cells of the fetuses demonstrated that cells 
from four of the fetuses were below 30% of the standard 
epoxide hydrolase activity and the other fifteen were above 
30% of the standard epoxide hydrolase activity (Buehler et 
al., 1990, Finnell et al., 1990). At birth all four of the 
infants with epoxide hydrolase activity below 30% of the 
standard had morphological defects classified as fetal 
hydantoin syndrome and the other fifteen infants were 
considered normal (Buehler et al., 1990, Finnell et al., 
1990) . 
The results of these studies suggest that the genotype 
of the developing fetuses may be used for determination of 
at risk fetuses (Bueler et al., 1990 and Finnell et al., 
1990). These experiments also support the theory that the 
intermediate which is removed by epoxide hydrolase is the 
active teratogen under actual therapeutic conditions. 
Pre implantation Mouse Embryonic Development: 
Mouse embryonic development begins after fertilization 
with the zygote. Directly after this union of the male and 
female gametes, the fertilized egg (Figure 3A) begins a 
series of mitotic cell divisions through the 2-cell (Figure 
3B), 4-cell (Figure 3C), and 8-cell stages. Then the embryo 
forms tight junctions and compacts upon itself to become a 
morula with 8-16 cells (Figure 3D). Further divisions and 
cavitation by pumping fluid into the center of the embryo to 
form a blastocoel is referred to as the blastocyst stage 
Figure 3E and F). The blastocyst which is composed of the 
inner cell mass (ICM) and the trophectoderm is capable of 
being implanted into the uterine wall (see Figure 3). 
Figure 3: Preimplantation stages of mouse 
zygote; (8) 2-cell stage; (e) 4-cell stage; 
blastocyst; (F) late blastocyst. (Rossant 
Embryo Culture: 
embryo development: 
(D) morula stage; 
and Pedersen ed., 
Ca) 
(E) early 
1986) • 
To be able to observe continual development of the 
preimplantation embryos, an in vitro culture system 
comparable to in vivo conditions needed to be established. 
In the past it has been difficult to derive in vitro grown 
cells which are comparable to those grown in vivo. Chatot 
et al., (1989) developed a modified mouse embryo culture 
medium, CZB medium, which promotes the development of 1-
cell embryos to the blastocyst stage in strains of mice that 
show a 2-cell "block" (development is arrested at the 2-cell 
stage) in vitro in other media. strains which do not 
normally block can also be cultured using CZB medium (Chatot 
et aI, 1990a). CZB differs from the other commonly used 
media because it contains glutamine and EDTA. This medium 
also lacks glucose and has a high lactate to pyruvate ratio. 
Embryos cultured in CZB medium are comparable to controls in 
expression of alkaline phosphatase (Chatot and Ziomek, 
unpublished observations), in general protein synthetic 
patterns (Poueymirou et al., 1989), in use of glutamine as 
an energy substrate (Chatot et al., 1990b) and in expression 
of the glutamine cycling enzyme glutaminase (Chatot et al., 
1990Ci Chatot and Kamper, 1992) but are slightly slower 
(approximately 1/2 day) in overall cell numbers compared to 
in vivo (Chatot et al., 1990a). This media provides close 
to normal in vitro development and can be used to study 
teratogenic effects on pre implantation embryos in vitro. 
-----------------------------------------------------
Materials and Methods 
Superovulation and Mating 
NSA females (Harlan Sprague Dawley, Indianapolis, 
Indiana) were superovulated by intraperitoneal injections of 
Pregnant Mare Serum Gonadotropin (PMS, 10 IU Sigma) followed 
48 hours later by an intraperitoneal injection of human 
Chorionic Gonadotropin (hCG, 5 IU Sigma). Females were 
mated immediately following hCG injection with B6SJLFl/J 
males (Jackson Laboratory, Bar Harbor, ME). 
Embryo Isolation: 
Females were sacrificed 47-53 hours post-hCG injection, 
the oviducts with a portion of the uterine horn were removed 
and placed into Hank's Balanced Salt solution (HBSS+BSA). 
The embryos were then flushed from the oviducts and washed 
in HBSS+BSA to remove debris and placed in holding drops of 
CZB medium. After being placed in holding drops, randomly 
distributed 2-cell embryos were washed through a drop of 
fresh CZB medium and placed in a final culture drop: 15 
embryos were cultured in a 50~1 drop. Cultures were gassed 
in a sealed culture chamber with 5% COz/5% 0z/90% Nz and 
incubated at 37°C for 48 hours. The embryos were cultured 
in the presence and absence of Dilantin (5, 10, 20, 50, and 
100 ~g/ml added to cultures in a total volume of 2 ~l). 
Controls were run with no Dilatin and vehicle controls 
included 2~1 of O.OlN sodium hydroxide (NaOH). 
Embryo Analysis: 
The embryos were collected after 48 hours of culture 
and were fixed in 4% paraformaldehyde solution in PBS. The 
embryos were scored for percent development to each 
preimplantation stage (2C, 4-8C, M, and B). The cultures 
were run in triplicate. In analyzing the data, the results 
were averaged across the samples for each concentration and 
the SEM was determined. 
Microsome Preparation and Titration: 
2 NSA females were injected with 0.1 ml B-napthoflavone 
(24mgjml) in chloroformjO.9% saline (diluted 1:10). Forty-
eight hours later, the mice were sacrificed and the livers 
were removed. The liver tissue slices were incubated for 15 
min in ice-cold 1.15% KCI and then homogenized on ice with 2 
volumes of ice-cold 1.15% KCl. The homogenate was 
centrifuged at 9000 x g for 20 minutes at 4°C. The 
supernatant was aliquoted and stored at -70°C. Total 
protein was determined using the Lowry Assay with BSA as the 
standard. Two cell embryo cultures were performed using an 
S9 fraction (10, 20, 40, 80, 100, and 160~gjml) for 
titration ± DPH (10 ~gjml). 
Results 
Dilantin was added directly to cultures of two cell 
mouse embryos both within and above the therapeutic range. 
Development of embryos to stages beyond two cell were 
evaluated after two days. Table 1 lists direct embryo 
results from 3-4 replicates of the DPH dose response curve. 
These results are represented as percent development to each 
stage in Figure 4 and 5. When DPH was added within the 
therapeutic range, development was retarded although this 
was not dose related (Figure 4). Cultures containing 5~g/ml 
DPH showed an increase in the number of embryos which only 
developed to the four-eight-cell stage. This was due to a 
reduction in the number of morula, but the number of 
blastocysts remained consistent with controls. At the 10 
and 20~g/ml levels a more pronounced effect was observed 
with overall reduced development, 3% (lo~g/ml) and 13% 
(20~g/ml) of the embryos did not develop beyond the two-cell 
stage and only 3% and 5% respectively of the two-cell 
embryos developed to the blastocyst stage at this 
concentration. This effect became more severe at the 50 and 
100~g/ml levels (58% and 97% of the embryos stayed at 
either the two or four-eight-cell stage and there were no 
blastocysts formed (Figure 5», however these levels are 
2.5-5 times the normal therapeutic level of the drug. 
Although a direct dose related response was absent, DPH did 
have an effect on development. These results suggested that 
the embryos may be capable of forming a teratogenic 
intermediate. 
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Figure 4: Percent mouse embryo development beyond 2-cell after di rect 
addition of DPH to cuI tures at concentrations within the therapeutic 
range. 
Table 1: 
[DPH]UgLml 
0 
O+NaOH 
5 
10 
20 
50 
100 
2C, 
Number of Embryos at Each stage 
of Development After Addition of DPH 
2C 4-8C M B M+B 
9 8 38 6 46 
9 7 27 9 36 
1 13 10 8 18 
5 12 22 1 23 
9 8 29 3 32 
5 13 13 0 13 
14 19 1 0 1 
N 
61 
52 
32 
40 
59 
31 
34 
two-cell errbryos; 4-8 C, four-eight-cell errbryos; H, 
morula; S, blastocyst: N, total nU1ber of errbryos cultured. 
DPH EFFECTS ON DEVELOPMENT 
(ABOVE THERAPEUTIC RANGE) 
_ 2C _ 4·ac I22Z3 M 0 BI t:.·:.-;····j M+BI 
100~---------------------------------, 
III 
o 
>-a: 
III 
:z 
w 
-' ~ 
C) 
... 
u. 
o 
to· 
z 
w 
75 
50 
U 25 
a: 
w 
II. 
o 
o O+NaOH 50 tOO 
OPH CONCENTRATION (IiV/ml) 
Figure 5: Percent mouse enilryo development beyond 2-cell after di rect 
addition of DPH to cultures at concentrations above the therapeutic 
range. 
To explore the question of the effect of a teratogenic 
intermediate on development, two cell cultures were exposed 
to an 89 microsome fraction capable of metabolizing DPH in 
the presence and absence of DPH. S9 fractions were prepared 
by the method described in Shanks et al. (1989). Lowry 
protein assays were used to determine the concentration of 
protein to titrate microsomes in the cultures. BSA was used 
as a standard (Figure 6). The protein concentration in the 
89 fraction was determined using the 1:1000 dilution from 
the standard curve to be 89.2mg/ml. The protein 
concentrations are shown in Table 2. 
Table 2: 
Lowry Assay for Protein concentration 
[B8Alt.£g/ml 
o 
50 
100 
200 
400 
E 
c 
0 
La 
t:, 
Q 
ci 
0.80 
0.55 
0.50 
0.45 
0.40 
0.35 
0.30 
0.25 
0.20 
0.15 
0.10 
0.05 
0.00 
0 
A~OM~ __ ~D~1~'=1~u~t~i~o~n~o~f~~8~9 __ ~A~OM~ __ ~[8=9]mg/ml 
0.00 1:100 0.467 480.11 
0.058 1:1000 0.093 89.23 
0.102 1:10,000 0.046 39.97 
0.212 1:100,000 0.030 23.20 
0.395 
Lowry Protein Standard Curve 
100 200 300 400 500 
aSA Conoentration (~glml) 
Figure 6: Lowry protein assay standard curve. 
As 89 fractions are often toxic at high concentrations, 
a dose titration was performed to determine a maximum 
concentration at which embryos will develop normally in the 
89 with no DPH added to the culture. cultures of two-cell 
embryos that were exposed to the 89 fraction did not show an 
appreciable toxic effect as compared to the controls in the 
experiment up to 80~g/ml (Table 3 and Figure 7). 
Table 3: 
Number of Embryos at Each stage of 
Development After the Addition 
of a Microsomal Fraction 
l§.9] M9Lml 2C 4-BC M B Abn N 
0 0 13 2 0 0 15 
10 0 9 0 0 3 12 
20 0 10 4 0 1 15 
40 0 0 2 0 13 15 
80 0 11 1 0 3 15 
100 0 0 0 0 4 4 
160 0 1 0 0 6 7 
Addition of P450 microsomes, no DPH 
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Figure 7: Titration of S9 microsome toxicity on 2-cell mouse enbryos. 
When an S9 fraction was added to the cultures along 
with 10~g/ml DPH the embryos did not develop or developed 
abnormally (Table 4 and Figure 8). This toxic effect 
suggests that a metabolite generated by the S9 system acting 
on DPH is the actual teratogen. 
Table 4: 
Number of Embryos at Each stage of 
Development After Addition of S9 + DPH 
[S9]ggLml 2C 4-8C M B 
O+NaOH 0 9 0 0 
10 0 0 0 0 
20 0 0 0 0 
40 0 0 0 0 
80 0 2 0 0 
100 0 1 0 0 
160 0 0 0 0 
DPH concentration in all dishes =10jtg/ml. 
Addition of P450 microsomes + DPH 
_ 2C 
_ 4·8C aM kQ'Za B 
0 100 0 
ar 
e 90 
.g 
: 80 
! 70 r 
c 
0 eo l-E 
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Figure 8: Effect of DPH + S9 microsomes on cultured 2-cell mouse 
enbryos. 
Discussion 
N 
12 
14 
15 
15 
19 
10 
13 
Embryos that were cultured in the presence of various 
concentrations of DPH (from 0-100~g/ml) showed an effect of 
the drug which did not represent a true dosage response. 
This suggests that an intermediate of Dilantin is the 
proximal teratogen and that the NSA x B,SJLF, mouse embryo 
is capable of synthesizing this intermediate. These results 
disagree with the observations of Chatot et al., (1984) 
where the direct addition of Dilantin to post-implantation 
rat embryo cultures produced no effect, however, Chatot et 
ale (1984) believe that at that stage in development, the 
rat is not capable of metabolizing the drug. The results do 
agree with the susceptibility of the mouse embryos to DPH 
effects as demonstrated by Finnell (1981) and Shanks et ale 
(1989) at post-implantation stages. A microsomal fraction 
(S9) was not found to be toxic to the embryos alone, 
however, when Dilantin (10~g/ml) was added to the cultures 
along with the S9 fraction, the toxicity of the system 
increases. Spielberg et ale (1981) and strickler et ale 
(1985) also found that the addition of a microsomal fraction 
did increase the toxicity of Dilantin to the lymphocytes in 
culture. Shanks et ale (1989) found that the addition of 
an S9 fraction + NADPH to cultures of post-implantation 
mouse embryos increased the teratotogenic effects of 
Dilantin. 
To continue to characterize the effects of this drug on 
preimplantation mouse embryo development, additional 
experiments could be suggested. Culture of one cell embryos 
± DPH ± S9 would allow us to assess the toxicity of Dilantin 
from the beginning of pre implantation development. Since at 
lo~g/ml S9 + 10~g/ml DPH a severe toxic effect was observed 
relative to controls, perhaps both the concentration of S9 
and DPH should be decreased or titrated downward to 
demonstrate a more specific retardation of development. 
Another strain of mouse either more susceptible or less 
susceptible to the teratogenic effects of Dilantin could be 
used. The capacity of the embryo to metabolize the drug via 
endogenous cytochrome P450 systems could also be 
investigated and the expression of epoxide hydrolase could 
be assessed in the embryo by RT-PCR or an enzymatic assay 
for epoxide hydrolase activity. The molecular mechanisms 
which cause growth retardation could be studied by examining 
how the expression of specific genes are affected, such as 
genes which control the cell cycle (cyclins) or genes for 
growth factor receptors like: EGF, PDGF, or IGF receptor. 
This could be performed using RT-PCR to look at RNA 
expression or antibodies to evaluate protein expression. 
These types of experiments would help to elucidate the 
mechanisms of the metabolism of Dilantin in preimplantation 
mouse embryos. 
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